What experience does Leapcure bring to uveal melanoma trials?

Leapcure runs recruitment for uveal melanoma across physician, advocacy, and digital channels: 14 physicians in our network have referred uveal melanoma patients directly to nearby sites, our patient success team has talked to 436 patients across channels, and 23 advocacy partners have surfaced 33 eligible and interested patients. Behind that funnel we bring infrastructure proven on both sides of this condition, 10+ Thyroid Eye Disease studies in ophthalmology and 1,000+ patients enrolled across oncology, applied to the uveal melanoma recruiting problem.

Why is uveal melanoma patient recruitment difficult?

Uveal melanoma is one of the rarest cancers in medicine, with only a few thousand new US cases each year, so the eligible pool is tiny and dispersed across a handful of specialized centers. Narrow protocol eligibility means most patient interest never converts to a site-ready referral, and because care is split between ocular oncologists, retinal specialists, and oncology teams, the path to a trial is rarely linear. Reaching and qualifying these patients takes physician relationships, trusted advocacy communities, and rigorous pre-screening, not volume advertising alone.

How does Leapcure's ophthalmology and oncology experience apply to uveal melanoma?

Uveal melanoma sits at the intersection of ophthalmology and oncology, and Leapcure has a track record in both. In ophthalmology, Leapcure has run 10+ Thyroid Eye Disease studies, enrolling 180+ patients and reaching 21,000+ through 100+ engaged ophthalmologists and 30+ advocacy groups across 10 countries, with a flagship study delivering 42% of all study enrollments. In oncology, Leapcure has engaged 50,000+ patients and enrolled 1,000+ across its portfolio. Those are track record from those programs, and the same recruiting muscle, physician networks, advocacy, and pre-screening, applies directly to uveal melanoma.

Which uveal melanoma advocacy organizations does Leapcure work with?

Leapcure works with 23 advocacy partners actively engaged on uveal melanoma. The named organizations anchoring that network include Ocular Melanoma Friends & Family, Metastatic Ocular Melanoma, Eye Cancer Foundation, A Cure In Sight, Ocular Melanoma Foundation, and Patients Like Me, alongside seven additional grassroots and community channels counted rather than individually named. These are active, co-developed relationships, not list purchases.

How does Leapcure handle uveal melanoma's narrow eligibility criteria?

Leapcure pre-screens every referral against the protocol's narrow eligibility criteria before it reaches a site. Because uveal melanoma's criteria mean most interest does not convert to a site-ready patient, that pre-screening exists to absorb the qualification work before it reaches a coordinator. Sites conduct official screening; Leapcure makes sure the patients who arrive are informed, eligible, and prepared, which protects scarce coordinator time at specialized centers.

What happens if our uveal melanoma trial is behind on enrollment?

Leapcure is built to stabilize enrollment that has stalled, especially for a rare, dispersed population. We activate our ocular-oncology physician network, 23 advocacy partners, and targeted digital outreach, pre-screen every referral against narrow eligibility so sites receive screen-ready patients, and match patients to the nearest capable site. We track referral quality and site engagement continuously and rebalance channels toward where enrollment can move fastest.

Leapcure brings proven ophthalmology and oncology recruitment infrastructure to one of medicine's rarest cancers: Uveal Melanoma.

Name: Uveal Melanoma Clinical Trial Recruitment | Leapcure
Creator: Leapcure

Uveal Melanoma sits at the intersection of ophthalmology and oncology, and its narrow eligibility turns most patient interest into screen fails. Leapcure reaches patients through a physician referral network, an advocacy ecosystem, and digital outreach, then pre-screens every referral so sites get patients ready to enroll.

Talk to our uveal melanoma team See how it works →

Physicians referring uveal melanoma patients

referred directly to nearby trial sites from Leapcure's network

Advocacy partners running awareness campaigns

actively engaged on uveal melanoma

436

Patients Leapcure's team talked to

across physician, advocacy, and digital channels

Understanding Uveal Melanoma as a Clinical Trial Indication

Uveal melanoma is the most common primary eye cancer in adults, yet it remains one of medicine's rarest cancers overall, with only a few thousand new cases diagnosed each year in the United States. It arises in the uveal tract of the eye, and in a substantial share of patients it eventually metastasizes, most often to the liver. Because it sits at the intersection of ophthalmology and oncology, patients are identified and managed by ocular oncologists and retinal specialists before oncology teams become involved, and the eligible trial population is small, geographically dispersed, and hard to reach through conventional recruitment.

For sponsors, that rarity and narrow eligibility are exactly what make uveal melanoma recruitment difficult. A protocol's criteria narrow an already tiny pool, so most patient interest never converts to a site-ready referral, and the patients who do qualify are spread across a handful of specialized centers. Reaching them takes physician relationships in ocular oncology, trusted advocacy communities, and pre-screening rigorous enough to absorb the eligibility work before it reaches a site.

Leapcure runs recruitment across all three of those channels for uveal melanoma. Fourteen physicians in Leapcure's network have referred uveal melanoma patients directly to nearby trial sites, our patient success team has talked to 436 patients across physician, advocacy, and digital channels, and 23 advocacy partners actively engaged on uveal melanoma have surfaced 33 eligible and interested patients to our team. Behind that funnel, Leapcure brings recruitment infrastructure proven on both sides of this condition. In ophthalmology, Leapcure has run 10+ Thyroid Eye Disease studies, enrolling 180+ patients and reaching 21,000+ through 100+ engaged ophthalmologists and 30+ advocacy groups across 10 countries, with a flagship Thyroid Eye Disease study delivering 42% of all study enrollments. In oncology, Leapcure has engaged 50,000+ patients and enrolled 1,000+ across its portfolio, including a hematologic gene therapy program that queued 20+ patients in four months while doubling site consenting rates. Those Thyroid Eye Disease and oncology figures are track record from those programs, applied to the uveal melanoma recruiting problem.

The Challenge

Uveal melanoma recruitment is a rarity-and-eligibility problem before it is a reach problem. A tiny pool, narrow criteria, and care split across two specialties all have to be solved at once.

One of the rarest cancers in medicine

Only a few thousand new uveal melanoma cases are diagnosed each year in the US, so the eligible trial pool is tiny and easy to miss with conventional, volume-led recruitment. Finding these patients at all is the first hurdle.

Leapcure's patient success team has talked to 436 uveal melanoma patients across physician, advocacy, and digital channels, reach built for a population most campaigns never find.

Narrow eligibility turns interest into screen fails

A protocol's criteria narrow an already small pool, so most patient interest never converts to a site-ready referral. Sending unconfirmed patients to sites wastes scarce coordinator time at specialized centers.

Leapcure pre-screens every referral against narrow eligibility criteria before it reaches a site; 23 advocacy partners engaged on uveal melanoma surfaced 33 eligible and interested patients to our team.

Care is split across ophthalmology and oncology

Uveal melanoma patients are identified by ocular oncologists and retinal specialists before oncology teams become involved, so the path to a trial is rarely linear and depends on relationships in both specialties.

14 physicians in Leapcure's network have referred uveal melanoma patients directly to nearby sites; separately, Leapcure has run 10+ Thyroid Eye Disease studies in ophthalmology and enrolled 1,000+ across oncology.

Eligible patients are dispersed across a few specialized centers

The small population is spread thinly across the country and concentrated at a handful of ocular-oncology centers, so recruitment has to reach patients wherever they are and route them to the nearest capable site.

Leapcure reaches dispersed rare-disease populations through advocacy and digital: on Thyroid Eye Disease programs it reached 21,000+ patients across 10 countries through 30+ advocacy groups.

Three steps. One strategy built for your uveal melanoma trial.

Leapcure applies its ophthalmology and oncology recruitment infrastructure to your protocol, your sites, and your eligibility criteria, reaching a rare population and confirming eligibility before referral.

Activate physician, advocacy, and digital channels

We activate an ocular-oncology physician referral network, 23 advocacy partners running awareness campaigns for the uveal melanoma community, and targeted digital outreach, matched to your eligibility criteria and site locations. Reaching a rare, dispersed population takes all three channels working together.

Pre-screen against narrow eligibility criteria

Uveal melanoma's narrow criteria mean most interest does not convert to a site-ready patient. Our patient success team engages every referral and pre-screens against protocol eligibility before a site sees them, absorbing that qualification work so coordinators are not buried in referrals that fail.

Refer only trial-ready patients to sites

We assign confirmed, prepared patients to the nearest capable site, then track referral quality and site engagement continuously and rebalance channels as sites engage. Sites conduct official screening; we make sure the patients who arrive are informed, eligible, and ready.

Uveal melanoma recruitment across physician, advocacy, and digital channels.

Physician referral network

14 physicians in Leapcure's network have referred uveal melanoma patients directly to nearby trial sites.

Advocacy ecosystem

23 advocacy partners actively engaged on uveal melanoma surfaced 33 eligible and interested patients to Leapcure's patient success team.

Patient reach across channels

436 patients talked to across physician, advocacy, and digital channels.

Ophthalmology proof (Thyroid Eye Disease)

A flagship Thyroid Eye Disease study delivered 42% of all study enrollments, part of 180+ enrolled across 10+ TED studies.

Four capabilities. Built in ophthalmology and oncology. Ready for uveal melanoma.

Leapcure reaches and qualifies uveal melanoma patients through an ocular-oncology physician network, an advocacy ecosystem, digital outreach and rigorous pre-screening, and answer-engine visibility delivered to your trial.

Ocular-Oncology Physician Referral Network

•14 physicians in Leapcure's network have referred uveal melanoma patients directly to nearby trial sites.
•Because uveal melanoma is identified by ocular oncologists and retinal specialists first, physician relationships surface patients who would never find a trial through advertising alone.
•This network sits on top of 100+ ophthalmologists engaged across Leapcure's Thyroid Eye Disease programs.

Advocacy Ecosystem and Digital Awareness

•23 named advocacy partners run awareness campaigns for the uveal melanoma community, surfacing eligible, interested patients rather than raw leads.
•These are established, co-developed relationships, not list purchases, paired with targeted digital outreach for a rare, dispersed population.
•Together they reach patients through the communities and channels they already trust.

Rigorous Pre-Screening and Cross-Portfolio Infrastructure

•Every referral is pre-screened against narrow eligibility criteria before a site sees the patient, so coordinators are not buried in interest that will not convert.
•Behind it stands recruitment infrastructure proven on both sides of this condition: 10+ Thyroid Eye Disease studies in ophthalmology and 1,000+ patients enrolled across oncology.
•That same model doubled site consenting rates on a completed oncology gene therapy program.

Answer-Engine and AI-Search Visibility

•Uveal melanoma patients and caregivers increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
•We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
•This puts your study where high-intent patients and caregivers are already searching.

An established advocacy ecosystem in uveal melanoma

Leapcure's uveal melanoma advocacy relationships are named, active, and co-developed, not list purchases. Twenty-three partners run awareness campaigns for the community; the six organizations below anchor that network, alongside seven additional grassroots and community channels counted rather than individually named.

Ocular Melanoma Friends & Family

Patient-and-caregiver community anchoring trust and awareness across the ocular melanoma population

Metastatic Ocular Melanoma

Community focused on metastatic disease, reaching the patients most relevant to advanced-stage trials

Eye Cancer Foundation

Eye-cancer advocacy organization extending reach and credibility for ocular-oncology recruitment

A Cure In Sight

Ocular melanoma nonprofit supporting patients and advancing trial awareness

Ocular Melanoma Foundation

Established foundation serving the ocular melanoma community and its caregivers

Patients Like Me

Patient network extending reach into the broader community around rare cancers

Grassroots and community channels

Seven additional grassroots and community support channels, counted rather than individually named

Living with uveal melanoma? A clinical trial may be an option.

If you or someone you care for is living with uveal melanoma, a clinical trial may offer access to investigational treatments that are not yet widely available. We know uveal melanoma is rare, that care is often split between eye specialists and oncologists, and that eligibility can feel complicated. Leapcure's team offers step-by-step support, answers your questions, and includes your family or caregivers wherever that helps.

See if a uveal melanoma trial may be right for you

Leapcure recruits uveal melanoma patients through a 14-physician referral network, 23 advocacy partners, and digital outreach, having talked to 436 patients across channels, and backs it with recruitment infrastructure proven in ophthalmology (10+ Thyroid Eye Disease studies) and oncology (1,000+ enrolled). Talk to our uveal melanoma team about your active or upcoming study.

Talk to our uveal melanoma team